Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Gynecology

Free Subscription Articles published in Ann Oncol Retrieve available abstracts of 93 articles: HTML format

Single Articles

July 2021
1. COLOMBO N, Ledermann JA
   Updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO Clinical Practice Guidelines.
   Ann Oncol. 2021 Jul 14. pii: S0923-7534(21)02182.
   PubMed    
   
   
   
2. DI VINCENZO A, Andrisani A, Vettor R, Rossato M, et al
   Estrogen and COVID-19: friend or foe?
   Ann Oncol. 2021;32:933-934.
   PubMed    
   
   
   June 2021
3. MIRZA MR, Coleman RL, Gonzalez-Martin A, Moore KN, et al
   Corrigendum to 'The forefront of ovarian cancer therapy: update on PARP inhibitors': [Annals of Oncology 31 (2020) 1148-1159].
   Ann Oncol. 2021 Jun 2. pii: S0923-7534(21)02020.
   PubMed    
   
   
   May 2021
4. SLAMON DJ, Neven P, Chia S, Jerusalem G, et al
   Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase 3 randomized MONALEESA-3 trial: updated overall survival.
   Ann Oncol. 2021 May 15. pii: S0923-7534(21)01553.
   PubMed     Abstract available
   
   
   April 2021
5. BELLONE S, Roque DM, Siegel ER, Buza N, et al
   A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793).
   Ann Oncol. 2021 Apr 28. pii: S0923-7534(21)01170.
   PubMed    
   
   
   March 2021
6. BAERT T, Ferrero A, Sehouli J, O Donnell DM, et al
   The Systemic Treatment of Recurrent Ovarian Cancer revisited.
   Ann Oncol. 2021 Mar 3. pii: S0923-7534(21)00155.
   PubMed     Abstract available
   
   
   
7. MOORE KN, Oza AM, Colombo N, Oaknin A, et al
   Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I.
   Ann Oncol. 2021 Mar 2. pii: S0923-7534(21)00157.
   PubMed     Abstract available
   
   
   January 2021
8. MONTOPOLI M, Zorzi M, Cocetta V, Prayer-Galetti T, et al
   Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients underwent anti-estrogenic therapy.
   Ann Oncol. 2021 Jan 29. pii: S0923-7534(21)00097.
   PubMed    
   
   
   
9. WU XH, Zhu JQ, Yin RT, Yang JX, et al
   Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase 3 trial.
   Ann Oncol. 2021 Jan 13. pii: S0923-7534(21)00008.
   PubMed     Abstract available
   
   
   
10. TOBALINA L, Armenia J, Irving E, O'Connor MJ, et al
    A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance.
    Ann Oncol. 2021;32:103-112.
    PubMed     Abstract available
    
    
    December 2020
11. PILIE PG, George A, Yap TA
    Patient selection biomarker strategies for PARP inhibitor therapy.
    Ann Oncol. 2020;31:1603-1605.
    PubMed    
    
    
    September 2020
12. MILLER RE, Leary A, Scott CL, Serra V, et al
    ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
    Ann Oncol. 2020 Sep 28. pii: S0923-7534(20)42164.
    PubMed     Abstract available
    
    
    
13. LAMBERTINI M, Peccatori FA, Demeestere I, Amant F, et al
    Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines.
    Ann Oncol. 2020 Sep 16. pii: S0923-7534(20)42448.
    PubMed    
    
    
    July 2020
14. LUEN SJ, Asher R, Lee CK, Savas P, et al
    Identifying oncogenic drivers associated with increased risk of late distant recurrence in post-menopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study.
    Ann Oncol. 2020 Jul 8. pii: S0923-7534(20)39934.
    PubMed     Abstract available
    
    
    June 2020
15. MIRZA MR, Coleman RL, Gonzalez-Martin A, Moore KN, et al
    The forefront of ovarian cancer therapy: update on PARP inhibitors.
    Ann Oncol. 2020 Jun 19. pii: S0923-7534(20)39891.
    PubMed     Abstract available
    
    
    May 2020
16. MILLSTEIN J, Budden T, Goode EL, Anglesio MS, et al
    Prognostic gene expression signature for high-grade serous ovarian cancer.
    Ann Oncol. 2020 May 27. pii: S0923-7534(20)39841.
    PubMed     Abstract available
    
    
    March 2020
17. BOLZE PA, You B, Lotz JP, Massardier J, et al
    Successful pregnancy in a cancer patient previously cured of a gestational trophoblastic tumor by immunotherapy.
    Ann Oncol. 2020 Mar 11. pii: S0923-7534(20)36076.
    PubMed    
    
    
    February 2020
18. WAKS AG, Cohen O, Kochupurakkal B, Kim D, et al
    Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
    Ann Oncol. 2020 Feb 20. pii: S0923-7534(20)36055.
    PubMed     Abstract available
    
    
    
19. KALLIALA I, Athanasiou A, Veroniki AA, Salanti G, et al
    Incidence and mortality from cervical cancer and other malignancies after treatment of cervical intraepithelial neoplasia: a systematic review and meta-analysis of the literature.
    Ann Oncol. 2020;31:213-227.
    PubMed     Abstract available
    
    
    October 2019
20. AMANT F, Berveiller P, Boere IA, Cardonick E, et al
    Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting.
    Ann Oncol. 2019;30:1601-1612.
    PubMed     Abstract available
    
    
    August 2019
21. AMANT F, Berveiller P, Boere I, Cardonick E, et al
    Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting.
    Ann Oncol. 2019 Aug 21. pii: 5552554. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2019
22. MATULONIS UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, et al
    Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.
    Ann Oncol. 2019;30:1080-1087.
    PubMed     Abstract available
    
    
    
23. GAILLARD SL, Coleman RL
    Identifying markers of immune response in ovarian cancer: does PD-L1 expression meet the mark?
    Ann Oncol. 2019;30:1025-1028.
    PubMed    
    
    
    May 2019
24. GAILLARD SL, Coleman RL
    Identifying markers of immune response in ovarian cancer: does PD-L1 expression meet the mark?
    Ann Oncol. 2019 May 21. pii: 5492551. doi: 10.1093.
    PubMed    
    
    
    
25. MALVEZZI M, Carioli G, Bertuccio P, Boffetta P, et al
    Reply to the Letter to the Editor: "European cancer mortality predictions for the year 2019 with focus on breast cancer, by Malvezzi M et al." by J. Marsden, H. Hamoda, On behalf of the British Menopause Society Medical Advisory Council.
    Ann Oncol. 2019 May 9. pii: 5487409. doi: 10.1093.
    PubMed    
    
    
    
26. MATULONIS UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, et al
    Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study.
    Ann Oncol. 2019 May 2. pii: 5482567. doi: 10.1093.
    PubMed     Abstract available
    
    
    
27. COLOMBO N, Sessa C, du Bois A, Ledermann J, et al
    ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent diseasedagger.
    Ann Oncol. 2019 May 2. pii: 5482247. doi: 10.1093.
    PubMed     Abstract available
    
    
    
28. JOLY F, Ahmed-Lecheheb D, Kalbacher E, Heutte N, et al
    Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study.
    Ann Oncol. 2019;30:845-852.
    PubMed     Abstract available
    
    
    
29. BUECHEL M, Herzog TJ, Westin SN, Coleman RL, et al
    Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option.
    Ann Oncol. 2019;30:721-732.
    PubMed     Abstract available
    
    
    
30. COLOMBO N, Sessa C, du Bois A, Ledermann J, et al
    ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.
    Ann Oncol. 2019;30:672-705.
    PubMed     Abstract available
    
    
    April 2019
31. LORUSSO D, Pignata S, Gonzalez-Martin A
    Chemotherapy-free treatments: are we ready for prime time?
    Ann Oncol. 2019;30:497-498.
    PubMed    
    
    
    
32. LIU JF, Barry WT, Birrer M, Lee JM, et al
    Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.
    Ann Oncol. 2019;30:551-557.
    PubMed     Abstract available
    
    
    March 2019
33. BUECHEL M, Herzog TJ, Westin SN, Coleman RL, et al
    Treatment of Patients with Recurrent Epithelial Ovarian Cancer for Whom Platinum is Still an Option.
    Ann Oncol. 2019 Mar 18. pii: 5384492. doi: 10.1093.
    PubMed     Abstract available
    
    
    
34. JOLY F, Ahmed-Lecheheb D, Kalbacher E, Heutte N, et al
    Long-term fatigue and quality of life among epithelial ovarian cancer survivors: A GINECO case/control VIVROVAIRE I Study.
    Ann Oncol. 2019 Mar 9. pii: 5372686. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2019
35. LIU JF, Barry WT, Birrer M, Lee JM, et al
    Overall survival and updated progression-free survival outcomes in a randomized phase 2 study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.
    Ann Oncol. 2019 Feb 7. pii: 5308594. doi: 10.1093.
    PubMed     Abstract available
    
    
    
36. TRIFANESCU OG, Topliceanu F, Gusoiu BA, Gales LN, et al
    24PReactive oxygen species and vascular endothelial growth factor (VEGF) in ovarian cancer patients.
    Ann Oncol. 2019;30.
    PubMed    
    
    
    
37. WEBB PM, Na R, Weiderpass E, Adami HO, et al
    Use of aspirin, other nonsteroidal anti-inflammatory drugs and acetaminophen and risk of endometrial cancer: the Epidemiology of Endometrial Cancer Consortium.
    Ann Oncol. 2019;30:310-316.
    PubMed     Abstract available
    
    
    
38. HUANG T, Tworoger SS, Willett WC, Stampfer MJ, et al
    Associations of early life and adulthood adiposity with risk of epithelial ovarian cancer.
    Ann Oncol. 2019;30:303-309.
    PubMed     Abstract available
    
    
    
39. TRIFANESCU OG, Topliceanu F, Gusoiu BA, Gales LN, et al
    Reactive oxygen species and vascular endothelial growth factor (VEGF) in ovarian cancer patients.
    Ann Oncol. 2019;30 Suppl 1:i8-i9.
    PubMed    
    
    
    
40. STONE A, Gebski V, Davidson R, Bloomfield R, et al
    Exaggeration of PFS by blinded, independent, central review (BICR).
    Ann Oncol. 2019;30:332-338.
    PubMed     Abstract available
    
    
    December 2018
41. HUANG T, Tworoger SS, Willett WC, Stampfer MJ, et al
    Associations of early life and adulthood adiposity with risk of epithelial ovarian cancer.
    Ann Oncol. 2018 Dec 21. pii: 5255827. doi: 10.1093.
    PubMed     Abstract available
    
    
    
42. WEBB PM, Na R, Weiderpass E, Adami HO, et al
    Use of aspirin, other nonsteroidal anti-inflammatory drugs and acetaminophen and risk of endometrial cancer: the Epidemiology of Endometrial Cancer Consortium.
    Ann Oncol. 2018 Dec 19. pii: 5253175. doi: 10.1093.
    PubMed     Abstract available
    
    
    October 2018
43. LEDERMANN JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, et al
    Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2018;29.
    PubMed    
    
    
    July 2018
44. BASU B, Krebs MG, Sundar R, Wilson RH, et al
    Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high grade serous ovarian and squamous non-small cell lung cancer.
    Ann Oncol. 2018 Jul 17. pii: 5055047. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2018
45. BRUSSELAERS N, Tamimi RM, Konings P, Rosner B, et al
    Different menopausal hormone regimens and risk of breast cancer.
    Ann Oncol. 2018 Jun 18. pii: 5039890. doi: 10.1093.
    PubMed     Abstract available
    
    
    
46. FOTOPOULOU C, Sehouli J, Mahner S, Harter P, et al
    HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer?
    Ann Oncol. 2018 Jun 4. pii: 5032848. doi: 10.1093.
    PubMed    
    
    
    May 2018
47. MIRZA MR, Pignata S, Ledermann JA
    Latest clinical evidence and further development of PARP inhibitors in ovarian cancer.
    Ann Oncol. 2018 May 10. pii: 4994787. doi: 10.1093.
    PubMed     Abstract available
    
    
    
48. MARTH C, Landoni F, Mahner S, McCormack M, et al
    Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2018 May 5. pii: 4993205. doi: 10.1093.
    PubMed    
    
    
    April 2018
49. RAY-COQUARD I, Morice P, Lorusso D, Prat J, et al
    Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2018 Apr 25. pii: 4983953. doi: 10.1093.
    PubMed    
    
    
    
50. CREUTZBERG CL, Bosse T
    Molecular risk stratification to direct therapy in endometrial cancer: ready for the clinic?
    Ann Oncol. 2018 Apr 14. pii: 4970554. doi: 10.1093.
    PubMed    
    
    
    March 2018
51. TAO MH, Chen S, Freudenheim JL, Cauley JA, et al
    Oral bisphosphonate use and lung cancer incidence among postmenopausal women.
    Ann Oncol. 2018 Mar 29. pii: 4956655. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2018
52. PICCIRILLO MC, Scambia G, Bologna A, Signoriello S, et al
    Quality of life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer.
    Ann Oncol. 2018 Feb 16. pii: 4864364. doi: 10.1093.
    PubMed     Abstract available
    
    
    
53. BIRKBAK NJ, Li Y, Pathania S, Greene-Colozzi A, et al
    Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple negative breast and serous ovarian cancers.
    Ann Oncol. 2018 Feb 14. pii: 4857262. doi: 10.1093.
    PubMed     Abstract available
    
    
    
54. KOMMOSS S, McConechy MK, Kommoss F, Leung S, et al
    Final Validation of the ProMisE Molecular Classifier for Endometrial Carcinoma in a Large Population-based Case Series.
    Ann Oncol. 2018 Feb 7. pii: 4844033. doi: 10.1093.
    PubMed     Abstract available
    
    
    
55. OSKAY-OZCELIK G, Alavi S, Richter R, Keller M, et al
    EXPRESSION III: Patient s Expectations and Preferences regarding Physician-Patient Relationship and Clinical Management. Results of the International NOGGO/ENGOT-ov4-GCIG study in 1,830 Ovarian Cancer Patients from European countries.
    Ann Oncol. 2018 Feb 5. pii: 4838337. doi: 10.1093.
    PubMed     Abstract available
    
    
    
56. BANERJEE S, Oza AM, Birrer MJ, Hamilton EP, et al
    Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared to pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.
    Ann Oncol. 2018 Feb 1. pii: 4833235. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2017
57. KHOSROW-KHAVAR F, Yin H, Barkun A, Bouganim N, et al
    Aromatase Inhibitors and the Risk of Colorectal Cancer in Post-Menopausal Women with Breast Cancer.
    Ann Oncol. 2017 Dec 27. pii: 4779926. doi: 10.1093.
    PubMed     Abstract available
    
    
    
58. FRIEDLANDER M, Rau J, Lee CK, Meier W, et al
    Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters - patient centered endpoints in trials of maintenan
    Ann Oncol. 2017 Dec 18. pii: 4756055. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2017
59. DE BOER SM, Wortman BG, Bosse T, Powell ME, et al
    Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer.
    Ann Oncol. 2017 Nov 27. pii: 4668721. doi: 10.1093.
    PubMed     Abstract available
    
    
    
60. PROVENCHER DM, Gallagher CJ, Parulekar WR, Ledermann JA, et al
    OV21/PETROC: A randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer.
    Ann Oncol. 2017 Nov 23. pii: 4654091. doi: 10.1093.
    PubMed     Abstract available
    
    
    
61. OKTAY K, Taylan E, Rodriguez-Wallberg KA, Bedoschi G, et al
    Goserelin Does Not Preserve Ovarian Function Against Chemotherapy-Induced Damage.
    Ann Oncol. 2017 Nov 3. doi: 10.1093.
    PubMed    
    
    
    
62. LEDERMANN JA
    Front-line therapy of advanced ovarian cancer: new approaches.
    Ann Oncol. 2017;28.
    PubMed     Abstract available
    
    
    
63. MONK BJ, Chan JK
    Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for advanced ovarian cancer?
    Ann Oncol. 2017;28.
    PubMed     Abstract available
    
    
    
64. MARTH C, Reimer D, Zeimet AG
    Front-line therapy of advanced epithelial ovarian cancer: standard treatment.
    Ann Oncol. 2017;28.
    PubMed     Abstract available
    
    
    
65. BOOKMAN MA, Okamoto A, Stuart G, Yanaihara N, et al
    Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference.
    Ann Oncol. 2017;28.
    PubMed     Abstract available
    
    
    
66. BRAND AH, DiSilvestro PA, Sehouli J, Berek JS, et al
    Cytoreductive surgery for ovarian cancer: quality assessment.
    Ann Oncol. 2017;28.
    PubMed     Abstract available
    
    
    
67. CHRISTIE EL, Bowtell DDL
    Acquired chemotherapy resistance in ovarian cancer.
    Ann Oncol. 2017;28.
    PubMed     Abstract available
    
    
    
68. DUSKA LR, Kohn EC
    The new classifications of ovarian, fallopian tube, and primary peritoneal cancer and their clinical implications.
    Ann Oncol. 2017;28.
    PubMed     Abstract available
    
    
    
69. ODUNSI K
    Immunotherapy in ovarian cancer.
    Ann Oncol. 2017;28.
    PubMed     Abstract available
    
    
    
70. EISENHAUER EA
    Real-world evidence in the treatment of ovarian cancer.
    Ann Oncol. 2017;28.
    PubMed     Abstract available
    
    
    
71. PUJADE-LAURAINE E
    New treatments in ovarian cancer.
    Ann Oncol. 2017;28.
    PubMed     Abstract available
    
    
    
72. PIGNATA S, C Cecere S, Du Bois A, Harter P, et al
    Treatment of recurrent ovarian cancer.
    Ann Oncol. 2017;28.
    PubMed     Abstract available
    
    
    
73. PARK SB, Kwok JB, Asher R, Lee CK, et al
    Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial.
    Ann Oncol. 2017;28:2733-2740.
    PubMed     Abstract available
    
    
    October 2017
74. NABIEVA N, Kellner S, Fehm T, Haberle L, et al
    Patient and tumor characteristics and their influence on early therapy persistence with letrozole in postmenopausal patients with early breast cancer.
    Ann Oncol. 2017 Oct 10. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2017
75. LORUSSO D, Pignata S
    Role of adjuvant chemotherapy in early stage endometrioid and clear cell ovarian cancer.
    Ann Oncol. 2017 Sep 18. doi: 10.1093.
    PubMed    
    
    
    
76. OSELEDCHYK A, Leitao MM Jr, Konner J, O'Cearbhaill RE, et al
    Adjuvant Chemotherapy in Patients with Stage I Endometrioid or Clear Cell Ovarian Cancer in the Platinum Era: A Surveillance, Epidemiology, and End Results Cohort Study, 2000-2013.
    Ann Oncol. 2017 Sep 18. doi: 10.1093.
    PubMed     Abstract available
    
    
    
77. REGAN MM, Walley BA, Francis PA, Fleming GF, et al
    Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT.
    Ann Oncol. 2017;28:2225-2232.
    PubMed     Abstract available
    
    
    March 2017
78. THAKER PH, Salani R, Brady WE, Lankes HA, et al
    A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852).
    Ann Oncol. 2017;28:505-511.
    PubMed     Abstract available
    
    
    April 2016
79. DI MAIO M, Perrone F
    Lessons from clinical trials on quality of life assessment in ovarian cancer trials.
    Ann Oncol. 2016.
    PubMed    
    
    
    
80. FRIEDLANDER M, Mercieca-Bebber RL, King MT
    Patient-reported outcomes (PRO) in ovarian cancer clinical trials-lost opportunities and lessons learned.
    Ann Oncol. 2016;27 Suppl 1:i66-i71.
    PubMed     Abstract available
    
    
    
81. PUJADE-LAURAINE E, Combe P
    Recurrent ovarian cancer.
    Ann Oncol. 2016;27 Suppl 1:i63-i65.
    PubMed     Abstract available
    
    
    
82. BOOKMAN MA
    Optimal primary therapy of ovarian cancer.
    Ann Oncol. 2016;27 Suppl 1:i58-i62.
    PubMed     Abstract available
    
    
    
83. LEDERMANN JA
    PARP inhibitors in ovarian cancer.
    Ann Oncol. 2016;27 Suppl 1:i40-i44.
    PubMed     Abstract available
    
    
    
84. KRZYSTYNIAK J, Ceppi L, Dizon DS, Birrer MJ, et al
    Epithelial ovarian cancer: the molecular genetics of epithelial ovarian cancer.
    Ann Oncol. 2016;27 Suppl 1:i4-i10.
    PubMed     Abstract available
    
    
    
85. MONK BJ, Minion LE, Coleman RL
    Anti-angiogenic agents in ovarian cancer: past, present, and future.
    Ann Oncol. 2016;27 Suppl 1:i33-i39.
    PubMed     Abstract available
    
    
    
86. MAHNER S, Trillsch F, Chi D, Harter P, et al
    Neoadjuvant chemotherapy in ovarian cancer revisited.
    Ann Oncol. 2016;27 Suppl 1:i30-i32.
    PubMed     Abstract available
    
    
    
87. REYNERS AK, Broekman KE, Glaudemans AW, Brouwers AH, et al
    Molecular imaging in ovarian cancer.
    Ann Oncol. 2016;27 Suppl 1:i23-i29.
    PubMed     Abstract available
    
    
    
88. COUKOS G, Tanyi J, Kandalaft LE
    Opportunities in immunotherapy of ovarian cancer.
    Ann Oncol. 2016;27 Suppl 1:i11-i15.
    PubMed     Abstract available
    
    
    
89. KAYE SB
    Progress in the treatment of ovarian cancer-lessons from homologous recombination deficiency-the first 10 years.
    Ann Oncol. 2016;27 Suppl 1:i1-i3.
    PubMed     Abstract available
    
    
    
90. POVEDA A, Romero I
    Advanced ovarian cancer: 20 years of ovarian cancer treatment.
    Ann Oncol. 2016;27 Suppl 1:i72-i73.
    PubMed    
    
    
    March 2016
91. MOSCHETTA M, George A, Kaye SB, Banerjee S, et al
    BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer.
    Ann Oncol. 2016.
    PubMed     Abstract available
    
    
    
92. FUJIWARA K, Monk BJ, Lhomme C, Coleman RL, et al
    Health-related Quality of Life in Women With Recurrent Ovarian Cancer Receiving Paclitaxel Plus Trebananib or Placebo (TRINOVA-1).
    Ann Oncol. 2016.
    PubMed     Abstract available
    
    
    
93. MATULONIS UA, Penson RT, Domchek SM, Kaufman B, et al
    Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multi-study analysis of response rates and safety.
    Ann Oncol. 2016.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: